Lilly UK

A leading innovation-driven company, Lilly makes medicines that help people live longer, healthier, more active lives. Lilly has a long heritage in discovering medicines for conditions that affect the human brain. We are applying the latest research in the fight against conditions such as Alzheimer’s, Parkinson’s, depression and schizophrenia.

Updated:
10 February 2016
Location:
National
Sectors:
Pharmaceutical

1. Action Plan

1. The National Dementia Declaration lists seven outcomes that the DAA are seeking to achieve for people with dementia and their carers. How would you describe your organisation’s role in delivering better outcomes for people with dementia and their carers?

A leading innovation-driven company, Lilly makes medicines that help people live longer, healthier, more active lives.  Starting with the work of our scientists and from collaborations with eminent scientific organizations, we place improved outcomes for individual patients at the centre of what we do.

Lilly has a long heritage in discovering medicines for conditions that affect the human brain.  We are applying the latest research in the fight against conditions such as Alzheimer’s, Parkinson’s, depression and schizophrenia.

Our UK based research scientists are focused on finding the next generation of treatments for Alzheimer’s and other neurodegenerative diseases causing dementia.  People with dementia and their doctors are involved in Lilly’s clinical trial programme at multiple locations across the UK.

Lilly provides additional support to dementia patients, carers and healthcare professionals through education.  Lilly is proud to have partnered with the Alzheimer’s Society for the past 4 years on the national ‘Worried About your Memory’ campaign, making significant inroads into raising awareness of symptoms and reducing the stigma associated to dementia.

Lilly’s vision is to make a significant contribution to humanity by improving global health. We will listen carefully to understand patient needs and work with health care partners to provide meaningful benefits for the people who depend on us.

2. What are the challenges to delivering these outcomes from the perspective of your organisation?

Current UK care pathways for dementia are not geared towards optimal outcomes for people with dementia.  There are a number of barriers associated with patients benefiting from an early and accurate diagnosis, including stigma associated with dementia, improved training for medical professionals, and access to dementia services such as memory clinics.

The significance and value of an early and accurate diagnosis for people with dementia, their family and carers is currently poorly understood within the UK, and will become increasingly important as new treatments evolve as a result of scientific innovation.

Other challenges facing people with dementia, and many other health conditions, are the poor rates of uptake of new medicines and the barriers to running clinical trials in the UK. These two obstacles are the major factors contributing to why many UK patients cannot access new medicines as quickly as our European counterparts.

Member website

www.lilly.co.uk

2. Actions

  • Innovation strategy

    Lilly is committed to its innovation strategy and to developing new medicines and diagnostics for the next generation of treatments to improve the lives of people with dementia and their carers. 

    Status:
    Planning

    2014 - Fourth Quarter Update

    Lilly has just announced collaboration with AstraZeneca in the fight against Alzheimer's disease. Lilly's vision is to make Alzheimer's dementia preventable by 2025.

     

    2012 - Third Quarter Update

    In progress (not in quarterly report of DAA).

    2012 - Second Quarter Update

    In progress (not in quarterly report of DAA).

    2012 - First Quarter Update

    In progress (not in quarterly report of DAA). 

  • World’s best scientists

    Lilly works with the world’s best scientists across industry and academia through a number of forums and initiatives. The result of these combined efforts, and those of other pharmaceutical companies, is the existence of a handful of potential new disease modifying therapies nearing the end of clinical trials.

    Status:
    Being implemented

    2014 - First Quarter Update

    Lilly has just announced collaboration with AstraZeneca in the fight against Alzheimer's disease. Lilly's vision is to make Alzheimer's dementia preventable by 2025.

    2012 - Third Quarter Update

    In progress (not in quarterly report of DAA).

    2012 - Second Quarter Update

    In progress (not in quarterly report of DAA).

    2012 - First Quarter Update

    In progress (not in quarterly report of DAA).

  • Active participant in the European IMI

    Lilly is also an active participant in the European Innovative Medicines Initiative (IMI); a series of joint public/private funded programmes designed to address key healthcare problems.  Lilly is working with several other pharmaceutical companies and academics to share data and run joint studies aimed at improving our basic understanding of Alzheimer’s disease.

    Status:

    2012 - Third Quarter Update

    In progress (not in quarterly report of DAA).  

    2012 - Second Quarter Update

    In progress (not in quarterly report of DAA). 

    2012 - First Quarter Update

    In progress (not in quarterly report of DAA). 

  • Association of British Pharmaceutical Industry

    Lilly is part of the Association of British Pharmaceutical Industry (ABPI) and in partnership with the ABPI is working to ensure UK patients have timely access to the latest innovate medicines.

    Status:

    2012 - Third Quarter Update

    In progress (not in quarterly report of DAA).

    2012 - Second Quarter Update

    In progress (not in quarterly report of DAA).

    2012 - First Quarter Update

    In progress (not in quarterly report of DAA).